Concepedia

Author

Steven Waggoner

Case Western Reserve UniversityORCID

Also Known As

Ali, Shamshad, S E Waggoner, S Waggoner, S. E. Waggoner, S. Waggoner, S.E. Waggoner, STEVEN WAGGONER, Steven E Waggoner, Steven E. Waggoner, Steven Waggoner

280

Publications

7.9K

Citations

44

H-Index

95

Concepts

All Affiliations

Case Western Reserve UniversityUniversity of ChicagoUniversity Hospitals of ClevelandRoswell Park Comprehensive Cancer CenterGynecologic Oncology Group
SW

About

Steven Waggoner is an author at Case Western Reserve University specializing in medicine, oncology, and gynecology oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

34

63

4.4K

2

Public Health

11

11

601

3

Health Sciences

10

11

1.3K

4

Cell Biology

2

2

129

5

Social Sciences

1

1

22

Steven Waggoner

×

94

Publications

6.8K

Citations

43

H-Index

YearCitations

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson,

The Lancet

2017

656

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal,

JAMA Oncology

2019

533

Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies

Arno J. Mundt, Anthony E. Lujan, Jacob Rotmensch,

International Journal of Radiation Oncology*Biology*Physics

2002

467

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Maurie Markman, John A. Blessing, Stephen C. Rubin,

Gynecologic Oncology

2005

243

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

Kian Behbakht, Michael W. Sill, Kathleen M. Darcy,

Gynecologic Oncology

2011

203

Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance

Anil Belur Nagaraj, Peronne Joseph, Olga Kovalenko,

Oncotarget

2015

195

Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma

Vivian E. von Gruenigen, Chunqiao Tian, Heidi E. Frasure,

Cancer

2006

193

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

David S. Miller, John A. Blessing, Carolyn Krasner,

Journal of Clinical Oncology

2009

182

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal,

Journal of Clinical Oncology

2018

138

Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry

Assieh A. Melikian, Peng Sun, Bogdan Prokopczyk,

Cancer Letters

1999

137

Page 1